Ilit Turgeman

503 total citations
20 papers, 349 citations indexed

About

Ilit Turgeman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pharmacology. According to data from OpenAlex, Ilit Turgeman has authored 20 papers receiving a total of 349 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 3 papers in Pharmacology. Recurrent topics in Ilit Turgeman's work include Cancer Immunotherapy and Biomarkers (5 papers), Cannabis and Cannabinoid Research (3 papers) and Neutropenia and Cancer Infections (3 papers). Ilit Turgeman is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Cannabis and Cannabinoid Research (3 papers) and Neutropenia and Cancer Infections (3 papers). Ilit Turgeman collaborates with scholars based in Israel, United States and Germany. Ilit Turgeman's co-authors include Gil Bar‐Sela, Mira Wollner, Irit Ben‐Aharon, Salvatore Campisi‐Pinto, Howard West, Avivit Peer, David Meiri, Gamal Hassoun, Lilach Bonstein and Gil M. Lewitus and has published in prestigious journals such as Annals of Oncology, Cells and Cancers.

In The Last Decade

Ilit Turgeman

17 papers receiving 341 citations

Peers

Ilit Turgeman

PHARM

ONCOL

IMMUN

EPIDE

SURGE

Lingsong Meng United States

Jingchun Zeng China

Roberto Paradisi Italy

Mei-Chi Hsu Taiwan

Maria Concetta Musacchio Italy

Konstantinos Panoulis Greece

Kang Liu China

Nirmal Verma India

Porsha Smith United States

Tobias Rachow Germany

Lingsong Meng United States

Ilit Turgeman

31 ×0.2

PHARM

32 ×0.3

ONCOL

21 ×0.4

IMMUN

31 ×0.7

EPIDE

23 ×0.6

SURGE

Citations per year, relative to Ilit Turgeman Ilit Turgeman (= 1×) peers Lingsong Meng

Countries citing papers authored by Ilit Turgeman

Since Specialization

Citations

This map shows the geographic impact of Ilit Turgeman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ilit Turgeman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ilit Turgeman more than expected).

Fields of papers citing papers by Ilit Turgeman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ilit Turgeman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ilit Turgeman. The network helps show where Ilit Turgeman may publish in the future.

Co-authorship network of co-authors of Ilit Turgeman

This figure shows the co-authorship network connecting the top 25 collaborators of Ilit Turgeman. A scholar is included among the top collaborators of Ilit Turgeman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ilit Turgeman. Ilit Turgeman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Turgeman, Ilit, et al.. (2025). Perceptions and needs of patients, caregivers and health professionals regarding an oncology community center: a qualitative study. Frontiers in Public Health. 13. 1569994–1569994.

Shalata, Walid, Sameh Daher, Sivan Shamai, et al.. (2024). Real-World Clinical Outcomes of Neoadjuvant Platinum-Based Chemotherapy with Nivolumab in Non-Small Cell Lung Cancer. Journal of Clinical Medicine. 13(21). 6568–6568.

Turgeman, Ilit & Howard West. (2023). Adolescents and Young Adults With Cancer. JAMA Oncology. 9(3). 440–440. 14 indexed citations

Cohen, Miri, Yosi Shamay, Johanna Czamanski‐Cohen, et al.. (2023). Linkage between Psychological Factors and Response to Immune Checkpoint Inhibitor Therapy: A Preliminary Study. Cells. 12(20). 2471–2471. 3 indexed citations

Turgeman, Ilit, et al.. (2023). Rhabdomyolysis Induced by the Interaction Between Ribociclib and Statins- Case Report and Literature Review. Breast Cancer Targets and Therapy. Volume 15. 47–50. 5 indexed citations

Turgeman, Ilit, et al.. (2023). Too Much of a Good Thing: The Association of Elevated Vitamin B12 Levels and Outcomes in Patients With Cancer Treated With Immunotherapy. Journal of Immunotherapy. 47(4). 117–122. 3 indexed citations

Turgeman, Ilit, et al.. (2022). P-295 Prognostic impact of clinico-pathologic parameters in early- and average-onset curatively resected colorectal cancer. Annals of Oncology. 33. S351–S351.

Turgeman, Ilit, et al.. (2022). Approach to Cancer Pain Management in Emergency Departments: Comparison of General and Oncology Based Settings. Pharmaceuticals. 15(7). 805–805. 2 indexed citations

Turgeman, Ilit & Irit Ben‐Aharon. (2021). Evolving treatment paradigms in esophageal cancer. Annals of Translational Medicine. 9(10). 903–903. 8 indexed citations

10.

Turgeman, Ilit, Tal Goshen‐Lago, Anat Reiner‐Benaim, et al.. (2021). Psychosocial perspectives among cancer patients during the coronavirus disease 2019 (COVID‐19) crisis: An observational longitudinal study. Cancer Reports. 5(5). e1506–e1506. 10 indexed citations

11.

Turgeman, Ilit & Gil Bar‐Sela. (2021). Effective Patient Selection for an Oncology-Dedicated Emergency Service: A Retrospective Study. JCO Oncology Practice. 17(10). e1567–e1575. 3 indexed citations

12.

Ben‐Aharon, Irit, Tal Goshen‐Lago, Ilit Turgeman, et al.. (2020). Young patients with cancer and a digital social network: the voice beyond the clinic. ESMO Open. 5(3). e000651–e000651. 11 indexed citations

13.

Bar‐Sela, Gil, Idan Cohen, Salvatore Campisi‐Pinto, et al.. (2020). Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome. Cancers. 12(9). 2447–2447. 84 indexed citations

14.

Goshen‐Lago, Tal, Moran Szwarcwort‐Cohen, Madeleine Benguigui, et al.. (2020). The Potential Role of Immune Alteration in the Cancer–COVID19 Equation—A Prospective Longitudinal Study. Cancers. 12(9). 2421–2421. 9 indexed citations

15.

Wollner, Mira, Sivan Shamai, Nir Peled, et al.. (2019). Immune-related Neutropenia Following Treatment With Immune Checkpoint Inhibitors. Journal of Immunotherapy. 43(2). 67–74. 14 indexed citations

16.

Turgeman, Ilit & Gil Bar‐Sela. (2018). Cannabis for cancer – illusion or the tip of an iceberg: a review of the evidence for the use of Cannabis and synthetic cannabinoids in oncology. Expert Opinion on Investigational Drugs. 28(3). 285–296. 52 indexed citations

17.

Turgeman, Ilit, Eugene Vlodavsky, Daniela Militianu, et al.. (2018). Fortuitous administration of denosumab in breast carcinoma with osteoclastic giant cells. Anti-Cancer Drugs. 29(5). 466–470. 4 indexed citations

18.

Turgeman, Ilit, Mira Wollner, Gamal Hassoun, Lilach Bonstein, & Gil Bar‐Sela. (2017). Severe complicated neutropenia in two patients with metastatic non-small-cell lung cancer treated with nivolumab. Anti-Cancer Drugs. 28(7). 811–814. 31 indexed citations

19.

Turgeman, Ilit & Gil Bar‐Sela. (2017). Cannabis Use in Palliative Oncology: A Review of the Evidence for Popular Indications.. PubMed. 19(2). 85–88. 28 indexed citations

20.

Lalazar, Gadi, Meir Mizrahi, Ilit Turgeman, et al.. (2015). Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial. Journal of Clinical Immunology. 35(4). 399–407. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact